Three BRAF inhibitors, vemurafenib (Tsai et al., 2008), dabrafenib (Hauschild et al., 2012), and encorafenib (Li et al., 2016) have been approved for the treatment of non-resectable BRAF V600E or V600K mutant melanoma and anaplastic thyroid cancer (Liu et al., 2019). This evidence concerns the gene BRAF and thyroid gland undifferentiated (anaplastic) carcinoma.